Patent ID: 9120804
Filing Date: 2015-09-01
Classification: A61K,A61P,C07D,Y02A

Abstract:
1. Compound selected from the group 3,3-dimethyl-6-[8-(2-oxa-6-aza-spiro[3.4]oct-6-yl)-[2,4]triazolo[1,5-a]pyrazin-2-ylamino]-1,3-dihydro-indol-2-one (“C81”), 3,3-dimethyl-6-[8-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamino]-1,3-dihydro-indol-2-one (“C91”), 3,3-dimethyl-6-[8-(2-oxa-6-aza-spiro[3.5]non-6-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamino]-1,3-dihydro-indol-2-one (“C92”), 7-[2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-ylamino)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-2,7-diaza-spiro[4.4]nonane-1,3-dione (“C95”), 7-[2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-ylamino)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-1,3,7-triaza-spiro[4.4]nonane-2,4-dione (“C108”), 2-[2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-ylamino)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-2,5,7-triaza-spiro[3.4]octane-6,8-dione (“C109”), 7-[2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-ylamino)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-1,3,7-triaza-spiro[4.5]decane-2,4-dione (“C110”), 7-[2-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-7-ylamino)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-1,3,7-triaza-spiro[4.4]nonane-2,4-dione (“C118”), 7-[2-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-ylamino)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-2,7-diaza-spiro[4.4]nonane-1,3-dione (“C127”), 6′-[[8-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl]amino]spiro[cyclobutane-1,3′-indoline]-2′-one (“C128”), [8-(2,7-diaza-spiro[4.4]non-2-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl]-(4,4-dimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-amine (“C129”), 6-[8-(1,4-dioxa-7-aza-spiro[4.4]non-7-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamino]-3,3-dimethyl-1,3-dihydro-indol-2-one (“C130”), 8-[2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-ylamino)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-2,8-diaza-spiro[4.5]decan-1-one (“C133”), (R)-7-[2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-ylamino)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-2,7-diaza-spiro[4.4]nonane-1,3-dione (“C136”), (S)-7-[2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-ylamino)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]-2,7-diaza-spiro[4.4]nonane-1,3-dione (“C137”), 6-[8-(6-oxo-2,7-diaza-spiro[4.4]non-2-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamino]-1,3-dihydro-indol-2-one (“C139”), 3,3-dimethyl-6-[8-(8-oxo-2,7-diaza-spiro[4.4]non-2-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamino]-1,3-dihydro-indol-2-one (“C140”), and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.